What happened to the coxibs on the way to the cardiologist?

Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):555-6. doi: 10.1158/1055-9965.EPI-14-3-EDA.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Cardiology / trends
  • Clinical Trials as Topic*
  • Cyclooxygenase Inhibitors / adverse effects*
  • Cyclooxygenase Inhibitors / pharmacokinetics
  • Cyclooxygenase Inhibitors / therapeutic use
  • Drug Approval
  • Humans
  • Lactones / adverse effects*
  • Lactones / pharmacokinetics
  • Lactones / therapeutic use
  • Product Surveillance, Postmarketing*
  • Sulfones / adverse effects*
  • Sulfones / pharmacokinetics
  • Sulfones / therapeutic use
  • United States

Substances

  • Cyclooxygenase Inhibitors
  • Lactones
  • Sulfones
  • rofecoxib